In Brief: Obstetrics and Gynecology Devices Panel
This article was originally published in The Gray Sheet
Obstetrics and Gynecology Devices Panel: Slated to discuss two draft guidance documents at a July 14-15 meeting in Rockville, Maryland. On July 14 the panel will discuss a draft guidance document on the study and evaluation of intrapartum continuous monitors for fetal pulse oximeters and fetal tissue pH. On July 15 the panel is scheduled to discuss a draft guidance document on the study and evaluation of in vivo devices for the detection of cervical cancer. For further information, contact FDA's Elisa Harvey at 301/594-1180...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.